Logo Image
|Videos|October 21, 2017

Incentivizing Pharma Companies to Develop Lifesaving Drugs

James S. Lewis, PharmD, FIDSA, shares different proposals shared in the health care community to incentivize pharmaceutical companies to develop needed drugs.

James S. Lewis, PharmD, FIDSA, Co-Director of Antibiotic Stewardship, Oregon Health and Science University, shares different proposals shared in the health care community to incentivize pharmaceutical companies to develop needed drugs. Dr. Lewis warns that although antibiotic stewardship efforts are helping to slow down resistance, they will not be able to stop it from happening. With bacteria continually gaining resistance to available drugs, newer agents are desperately needed. In addition, Dr. Lewis also explains why susceptibility testing should be developed in parallel to new drugs that are being tested and developed.

Related to this article

View more
How The Food Safety Surveillance Infrastructure Works in the US
How The Food Safety Surveillance Infrastructure Works in the US
In the first episode of our news series looking at the food safety network, Lynette Johnston, PhD, offers insights into how the federal government surveillance infrastructure operates, and how epidemiologists serve as food detectives in determining bacterial pathogens and potential foodborne outbreaks.
Read more
This Week's Top 5 Infectious Disease News Stories: September 12-September 18, 2026
This Week's Top 5 Infectious Disease News Stories: September 12-September 18, 2026
In this week's top infectious disease stories, a Pennsylvania teen became the state's fourth measles death in weeks, the CDC reported a 17% summer surge in rabies exposure calls, new research revisited whether cefepime raises mortality risk, a multihospital review examined ceftriaxone's safety after state alerts, and examining Legionella pneumonia diagnostics.
Read more
Ceftriaxone Safety: Separating Signal From Risk
Ceftriaxone Safety: Separating Signal From Risk
A retrospective multihospital study found that severe adverse events occurred at similarly low rates with ceftriaxone and other IV cephalosporins suggesting there is no evidence to support avoiding ceftriaxone despite recent health department safety alerts.
Read more
Treatment of Latent Tuberculosis in a Trice
Treatment of Latent Tuberculosis in a Trice
A retrospective study of 225 patients across Cook County Department of Health clinics found that the novel 1-month 1HP regimen (isoniazid plus rifapentine) for latent TB infection had a completion rate comparable to standard longer regimens and was well tolerated, suggesting it may be a viable shorter alternative.
Read more
Peggy Lillis Foundation Will Honor C diff Advocates at Annual Gala
Peggy Lillis Foundation Will Honor C diff Advocates at Annual Gala
The Peggy Lillis Foundation will host its 17th Annual Changing the Odds Gala this month in New York City, and it will include a casino, fellowship amongst the C diff community, and an award ceremony honoring a physician-scientist, philanthropist, a researcher, and a patient advocate for their contributions to C difficile awareness, treatment, and prevention.
Read more